Business Wire

CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors and Names Tony Coles, M.D., Chairman of the Board to Enhance Drug Development and Commercialization Expertise

Del

CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases, today announced the appointment of Pablo J. Cagnoni, M.D., to its board of directors. The Company also named current board member, Tony Coles, M.D., as new Chairman of the Board. Dr. Coles succeeds Bradley Bolzon, M.D., Managing Director of Versant Ventures and Founding Chairman since 2013.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160317005477/en/

CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors (Photo: Business Wire)

CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors (Photo: Business Wire)

“As Pablo and Tony transition into their new roles, I would like to thank Brad for his leadership and commitment as our Chairman since inception, and am very pleased he will continue guiding the Company as a director,” said Rodger Novak, M.D., Chief Executive Officer of CRISPR Therapeutics. “Pablo is an ideal addition with his deep experience in drug development, translating breakthrough therapeutic approaches into highly innovative drugs for people with cancer and other debilitating diseases. His experience partnering with the medical community to transform treatment paradigms will help expedite the development of novel therapeutics derived from our proprietary technology platform.”

During Dr. Cagnoni’s 25-year career as an oncologist and biopharmaceutical innovator, he has played a key role in the development, approval and/or commercialization of several life-changing medicines, most notably Tarceva®, Afinitor®, and Kyprolis®. Dr. Cagnoni, who has served as Managing Director of MPM Capital since 2015, is currently President and Chief Executive Officer of Tizona Therapeutics and Executive Chairman of Blade Therapeutics. Before this, Dr. Cagnoni served as President of Onyx Pharmaceuticals, a subsidiary of Amgen, where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio.

“I am honored and excited to join CRISPR Therapeutics’ Board at a time when its technology has the potential to revolutionize the treatment of some of the world’s most intractable diseases,” said Dr. Cagnoni. “CRISPR Therapeutics has the technology, scientific rigor, resources, world-class team and partners necessary to realize its ambitious mission.”

CRISPR Therapeutics is focused on the discovery and development of potential cures for serious diseases using its proprietary CRISPR-Cas9 gene editing technology. The Company’s multi-disciplinary team of world-class drug developers, clinicians and academics is working on its own proprietary product pipeline and also partnering with some of the world’s leading pharmaceutical and biotechnology companies to translate this technology into breakthrough human therapeutics. The foundational CRISPR-Cas9 patent estate for human therapeutic use was licensed from scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics recently entered into substantial strategic partnerships with Vertex Pharmaceuticals and Bayer.

Prior to his tenure at Onyx/Amgen, Dr. Cagnoni served in executive global development roles at Novartis Oncology, Allos Therapeutics (acquired by Spectrum Pharmaceuticals) and OSI Pharmaceuticals (acquired by Astellas). Dr. Cagnoni earned his medical degree from the University of Buenos Aires School of Medicine, and completed his fellowships in Hematology and Oncology at Mount Sinai Medical Center in New York and in stem cell transplantation at the University of Colorado Health Sciences Center. Before joining industry, he served as Assistant Professor of Medicine at the University of Colorado Bone Marrow Transplant Program.

Dr. Coles joined the Board of Directors of CRISPR Therapeutics in December 2015, and currently serves as Chairman and Chief Executive Officer of Yumanity Therapeutics, a biotechnology company focused on transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Prior to founding Yumanity, Dr. Coles was Chairman and Chief Executive Officer of Onyx Pharmaceuticals. Previously, he held various executive and leadership positions at NPS Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers Squibb Company and Merck & Co.

CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.

Contact information

W2O Group for CRISPR
Jennifer Paganelli, 347-658-8290
jpaganelli@w2ogroup.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Hilton Led Hospitality Industry in Customer Innovations and Recorded Best Ever Growth in 201722.1.2018 13:00Pressemelding

In 2017, Hilton (NYSE: HLT) achieved record-setting growth, unveiled industry-leading innovations, and introduced new benefits for guests and Team Members. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122005292/en/ Hilton Led Hospitality Industry in Customer Innovations and Recorded Best Ever Growth in 2017 (Graphic: Business Wire) 2017 was a year of industry firsts, including the launch of Five Feet To Fitness, Hilton Honors loyalty program partnership with Amazon, Tapestry Collection by Hilton, and workplace innovations that received international recognition. It was also the year that Hilton introduced a ground-breaking concept – Connected Room – the first truly mobile-centric hotel room that will let guests personalize and control their stays from the award-winning Hilton Honors smartphone app. “Last year was another pioneering year for our team around the world, with the launch of new technologies, brands, and partn

European Commission Approves ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy– Providing an Innovative Treatment Option to Patients22.1.2018 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) extended the current conditional marketing authorization of ADCETRIS® (brentuximab vedotin) and approved ADCETRIS for the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, which is expressed on skin lesions in approximately 50 percent of patients with CTCL. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on November 9, 2017. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122005037/en/ “CTCL is a subtype of non-Hodgkin lymphoma that primarily involves the skin; it typically presents with red, scaly patches or thickened plaques of skin that often mimics eczema or psoriasis and can have a substantial impact on patients’ self-esteem. There a

Ingersoll Rand Announces Acquisition of ICS Group Holdings Limited, a Leading European Temperature Control and HVAC Solutions Provider22.1.2018 11:30Pressemelding

Ingersoll-Rand plc (NYSE:IR), a world leader in creating comfortable, sustainable and efficient environments, today announced the acquisition of United Kingdom-based ICS Group Holdings Limited (ICS Cool Energy). ICS Cool Energy will be part of the company’s Commercial Heating, Ventilation and Air Conditioning (HVAC) business. ICS Cool Energy is a privately owned temperature control and HVAC solutions and services company that specializes in temporary rental of energy efficient chillers for commercial and industrial buildings across Europe. It also sells, permanently installs and services high performance temperature control systems for all types of industrial processes. “ICS Cool Energy is a leader in the high margin rental services business with a reputation for strong customer service, helping building owners enhance productivity and reduce environmental impact,” said Dave Regnery, executive vice president of Ingersoll Rand. “This acquisition is a strong fit with our Trane business,

The Geneva Association: Insurance Industry Taking Action in Addressing Climate Change, Although External Hurdles Remain22.1.2018 10:00Pressemelding

The insurance industry is contributing significantly to building socio-economic resilience to climate change and supporting the transition to a low-carbon economy in their role as risk management experts and investors, although a number of challenges are hindering the industry’s efforts to scale up its contribution, according to a new research report from The Geneva Association, the leading international think tank of the insurance industry. The report ‘Climate Change and the Insurance Industry: Taking Action as Risk Managers and Investors’ is based on interviews with 62 C-level executives of globally active insurance and reinsurance companies, and offers insights into the role of the insurance industry in addressing climate change adaptation and mitigation. Anna Maria D’Hulster, Secretary General of The Geneva Association, commented: “The study has confirmed that climate change is a topic that has made its way up to the boardrooms of the insurance industry, although insurers are neith

Yonnic GmbH Enriches Targeting for Clients with Digital Element’s IP Geolocation Data22.1.2018 09:03Pressemelding

Leading IP geolocation intelligence company, Digital Element, has today announced that Yonnic GmbH, the industry pioneer of performance marketing solutions, has chosen its NetAcuity technology to boost targeting efficiency for its clients. Yonnic delivers brand relevance for its clients by uncovering and converting consumer intent through its proprietary process Intent-Based Planning tool. Its core application, CloudTDS, provides traffic routing and content delivery based upon a wide range of customisable rules and settings, such as geographical targeting and device specific targeting. By incorporating Digital Element’s NetAcuity data into its solution, Yonnic is able to upgrade its geographical targeting to provide the most accurate solution to its clients. Adding additional IP intelligence datasets such as connection speed, mobile carrier, internet service provider and whether a home or business connection is being used enables Yonnic to further boost its targeting and analytics capa

Vertex Hires Regional Leader to Expand European Presence22.1.2018 08:53Pressemelding

Vertex, Inc., a leading provider of tax automation solutions, announced Akram El-Rikabi has joined the management team as the regional leader to head European operations. This announcement reflects the company’s growing global presence in the European marketplace and dedication to the international business community. Vertex Vice President of Global Business Development Rebecca Polley states, “Having a proven leadership team and strong regional presence in Europe is critical to engaging with our multinational clients, prospects and partners. In his role, Akram will support Vertex’s growth initiatives by leveraging his expertise in helping customers realize strategic value in their technology investments, especially in the increasingly complex global tax landscape.” El-Rikabi brings 20 years of experience in finance, economics, banking, global partnerships and software management, having worked with global corporations in over 20 countries. Most recently, El-Rikabi was the regional sale

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom